Halozyme Therapeutics HALO Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's return on invested capital?
- Halozyme Therapeutics (HALO) reported return on invested capital of 34.1% in Q3 2025.
- How has Halozyme Therapeutics's return on invested capital changed year-over-year?
- Halozyme Therapeutics's return on invested capital increased by 45.8% year-over-year, from 23.4% to 34.1%.
- What is the long-term trend for Halozyme Therapeutics's return on invested capital?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's return on invested capital has grown at a -7.6% compound annual growth rate (CAGR), from 36.7% to 26.8%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.